After the separation, the New BD is expected to have fiscal 2024 revenue of approximately $17.8 billion1, with a $70+ billion addressable market growing at approximately 5%. New BD is expected to benefit from strong, durable cash flow and a best-in-class recurring revenue profile of over 90% that will help drive focused investment, accelerate New BD’s innovation pipeline and systematically enhance growth and margin targets. Post-separation, New BD intends to focus on maintaining a strong balance sheet, making investments in innovation, returning capital to shareholders https://betinwin-bd.com/bd/ via dividend and share repurchases, and maintaining its investment grade credit rating. The BD Life Sciences segment delivers innovative solutions from discovery to diagnosis, continually advancing science and clinical outcomes across infectious disease and cancer. Offerings include preanalytical solutions for sample management; immunology research solutions, including flow cytometry and multiomics tools; microbiology and molecular diagnostics; lab automation and informatics solutions; and differentiated reagents and assays.

BD Integrated Diagnostic Solutions

At BD, we believe that people are at the heart of every breakthrough, solution, and step forward. Our Purpose drives us to create innovative solutions that make a meaningful impact on advancing the world of health™. We know that possibilities are endless when people feel supported and inspired. From our robust benefits to our inclusive, growth-focused culture, we’re here to help you thrive both professionally and personally.

Enabling you to advance patient care at each step

98% of hospital inpatients undergo some form of diagnostic testing.1 Diagnostic tests for blood culture, blood chemistry and urine affect nearly every patient in your facility. And while ensuring patient care is your primary priority, you may also face other challenges such as complex tests, suboptimal workflows, preanalytical errors and staffing shortages. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement.

By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at /company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. BD is one of the largest global medical technology companies in the world and is advancing the world of healthTM  by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers.

Advancing the world of health™

The Biosciences and Diagnostic Solutions business is also expected to benefit from enhanced focus and investments as a pure-play Life Sciences Tools and Diagnostics leader. The business is expected to have approximately $3.4 billion in fiscal 2024 revenue with a $22+ billion addressable market growing at mid- to high-single-digits, with more than 80% recurring revenue, and approximately 30% adjusted EBITDA margins. Biosciences is a leader in immunology and cancer research solutions and related clinical diagnostics, including flow cytometry instruments and reagents, and has innovative single-cell multiomics tools.

Diagnostic Solutions is a leader in microbiology and infectious disease diagnostics, including molecular diagnostics, cervical cancer screening, microbiology automation and point-of-care offerings. Both businesses have strong leadership teams with unparalleled commercial, engineering and R&D expertise, and are dedicated to bringing the next generation of high-quality innovations to researchers, clinicians and patients. BD is one of the largest global medical technology companies in the world and is advancing the world of health™ by improving medical discovery, diagnostics and the delivery of care. BD is a global medical technology company that is advancing the world of healthTM by improving medical discovery, diagnostics and the delivery of care. BD is the one of the largest medical technology companies in the world and is advancing the world of health™ by improving medical discovery, diagnostics and the delivery of care. Non-GAAP Financial MeasuresThis news release contains certain non-GAAP financial measures.

reason to partner with BD on Integrated Diagnostic Solutions

Our Corporate Sustainability strategy—a four-pillar framework called Together We Advance—embraces the connections and interdependence between company health, planet health, community health and human health. Through this framework, we address the most relevant Corporate Sustainability issues for our business and stakeholders. Based in Mexico City, to produce syringes, needles and clinical thermometers for the Mexican market. 1991 BD opens a central distribution center in Temsee, Belgium to ship medical products across Europe, the middle east, and Africa. 1995 A joint venture was established in China to produce medical products for China.

In addition, excluded from adjusted EBIDTA margin are certain costs that BD does not allocate to its organizational units, such as, among other things, foreign exchange, certain general and administrative expenses, and share based compensation expense. BD does not attempt to provide reconciliations of forward-looking adjusted EBITDA margin to the comparable GAAP measure because the impact and timing of these potential charges or gains are inherently uncertain and difficult to predict and are unavailable without unreasonable efforts. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a material impact on GAAP measures of the Biosciences and Diagnostic Solutions business’s financial performance.

BD and more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare. BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.